Autonomix Medical (AMIX) said Thursday that regulators in Uzbekistan have approved the start of a clinical trial evaluating the safety and efficacy of using transvascular energy to ablate problematic nerves to mitigate pain in patients with various types of cancer.

Autonomix said it is on track to commence enrollment this month.

The company previously led proof-of-concept testing of its pain therapy in patients with pancreatic cancer but said it believes its process could eventually be used to treat other conditions, with potential applications for cardiology, gastroenterology and hypertension, as well as treating chronic pain.

Autonomix Medical shares were 14% lower in recent trading.

Price: 1.38, Change: -0.24, Percent Change: -14.81